查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
2022-2029 年全球卵巢癌市场
市场调查报告书
商品编码
1140756

2022-2029 年全球卵巢癌市场

Global Ovarian Cancer Market - 2022-2029
出版日期: | 出版商: DataM Intelligence | 英文 200 Pages | 商品交期: 约2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

市场概览

全球卵巢癌市场预计在预测期内（2022-2029 年）将以 16% 的复合年增长率增长。

卵巢癌是一种致命的妇科癌症，在全球女性中排名第七。大多数患有卵巢癌的女性被诊断为晚期，这是最难治疗的。化疗和手术通常用于治疗卵巢癌。

市场动态

主要驱动因素是卵巢癌发病率的上升、技术创新临床试验的增加、医疗保健成本的上升、卵巢癌治疗中联合疗法的使用以及老年人口的增加。

卵巢癌负担加重和女性人口老龄化正在推动全球市场的增长。

患病率的上升和女性老年人口的增加正在推动全球市场的增长。例如，根据国际世界癌症研究基金会的数据，卵巢癌是女性中第八大最常见的癌症，也是总体上第十八大□□最常见的癌症。根据美国国立卫生研究院的数据，2020年全球将有超过313,000例卵巢癌新病例和207,252例卵巢癌新死亡病例，使其成为最常见的类型，占所有卵巢癌的90%或更多。此外，根据美国国立卫生研究院的数据，随着年龄的增长，女性患卵巢癌的风险会增加，因此越来越多的老年女性正在推动全球市场的增长。例如，到 2020 年，65 岁及以上的人口将达到 7.27 亿。女性的寿命比男性长，因此她们占老年人的大多数。

在卵巢癌方面，癌症治疗的成本正在製约全球市场的增长。

然而，癌症治疗成本高、卵巢癌缺乏准确诊断以及新兴和低收入国家的低意识预计将抑制市场。对于没有健康保险的患者，晚期癌症的手术和化疗费用可能在 20,000 美元到 200,000 美元之间。

全球卵巢癌市场 - 行业分析

《世界卵巢癌报告》根据波特五力、创新、新产品发布、定价和管道分析等各种行业因素对市场进行了深入分析。

细分分析

预测期内（2022-2029年），卵巢癌市场有望以影像检测市场为主

2021年，上皮性卵巢癌将主导全球市场。由于上皮癌是最常见的卵巢癌类型，预计在整个预测期间（2022-2029 年）将显示出类似的趋势。许多临床研究正在进行中。例如，根据英国癌症研究，100 个卵巢肿瘤中约有 90 个（90%）是上皮肿瘤，根据 ClinicalTrails.Gov. 的增加，已经在上皮肿瘤中进行了 200 多项临床研究。据 Gov 称，上皮性卵巢癌有 200 多项介入试验。一个例子是 HIPEC（腹膜内高温化疗）用于治疗復发性卵巢癌、早期復发（小于 3 个月）或一线标准治疗的 p53 突变上皮性卵巢癌的 III 期随机试验。卡铂联合 Wee-1 抑製剂 MK-1775 在晚期疾病患者中的 II 期药理学试验。 GINECO II 期研究评估贝伐单抗、奥拉帕尼和 Durvalumab (MEDI 4736) 在復发性晚期上皮性卵巢癌中的安全性和有效性，具有高叶酸受体 Alpha 的铂耐药性，高度进展 有许多试验，包括 3 期试验Milbetaxin 单药治疗高级别上皮性卵巢癌、原发性腹膜癌和输卵管癌。

区域分析

预计亚太地区将主导全球卵巢癌市场。

预计亚太地区将主导全球卵巢癌市场，因为它的卵巢癌发病率最高，占世界人口的大多数。例如，据WHO统计，2020年东亚卵巢癌新增病例71353例，死亡45690例，东南亚卵巢癌新增病例31169例，死亡31169例20012、59730南亚和中亚的卵巢癌新增病例和死亡病例为 41407 例，西亚因卵巢癌进展新增病例为 8507 例，死亡病例为 5827 例。另外，亚太地区是世界上人口最多的国家，印度和中国，比如2021年印度的人口是14.12亿，而中国的人口是14.26亿，我在这里。亚太地区占世界人口的60%，带动了该地区卵巢癌市场的增长。

竞争格局

在全球卵巢癌市场运营的主要公司有罗氏、葛兰素史克、阿斯利康、勃林格殷格翰、百时美施贵宝、诺华、新基、安进、辉瑞和默克。领先企业正在采取各种策略，如产品发布、併购、合作伙伴关係和合作，为全球卵巢癌市场的增长做出贡献。例如，2022 年 8 月 16 日，葛兰素史克收购了 Affinivax, Inc.。此外，2021 年 12 月 22 日，诺华收购了 Gyroscope Therapeutics。

AstraZeneca plc

概述

AstraZeneca plc 是一家领先的製药和生物技术公司，服务于癌症、心血管、胃肠道、传染病、神经科学、呼吸和炎症。 AstraZeneca plc 成立于 1999 年，总部位于英国剑桥。

产品组合

AstraZeneca plc的卵巢癌产品组合包括 LYNPARZA。

全球卵巢癌报告将提供对大约 40 多个市场数据表、45 多个图表和 200 多页（大约）的访问。

内容

  • 调查方法
  • 调查目的和范围

第 2 章市场定义和概述

第 3 章执行摘要

第 4 章市场动态

  • 市场影响因素
    • 促进因素
      • 卵巢癌负担不断上升
      • 老年女性人口增加
    • 抑制因素
      • 高成本
      • 缺乏治疗选择
    • 商机
    • 影响分析

第 5 章行业分析

  • 波特五力分析
  • 供应链分析
  • 监管分析

第 6 章 COVID-19 分析

  • COVID-19 的市场分析
    • COVID-19 之前的市场情景
    • COVID-19 的当前市场情景
    • COVID-19 后或未来情景
  • COVID-19 期间的价格动态
  • 供需范围
  • 大流行期间与市场相关的政府举措
  • 製造商的战略举措
  • 总结

第 7 章按类型

  • 上皮性卵巢癌
  • 生殖细胞卵巢癌
  • 基质细胞卵巢癌
  • 小细胞卵巢癌

第 8 章按治疗类型

  • 靶向治疗
  • 手术治疗
  • 化疗
  • 免疫疗法
  • 其他

第 9 章按诊断类型

  • 验血
  • 图像检查
  • 腹腔镜检查
  • 结肠镜检查
  • 其他

第 10 章药物类别

  • PARP抑製剂
  • 血管生成抑製剂
  • PD-L1抑製剂

第 11 章最终用户

  • 医院和诊所
  • 诊断中心
  • 癌症研究中心
  • 其他

第 12 章按地区划分

  • 北美
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 法国
    • 意大利
    • 西班牙
    • 其他欧洲
  • 南美洲
    • 巴西
    • 阿根廷
    • 其他南美洲
  • 亚太地区
    • 中国
    • 印度
    • 日本
    • 澳大利亚
    • 其他亚太地区
  • 中东和非洲

第 13 章竞争格局

  • 主要发展和战略
  • 公司份额分析
  • 产品基准

第 14 章公司简介

  • AstraZeneca
    • 公司概况
    • 产品组合和描述
    • 主要亮点
    • 财务摘要
  • Roche
  • GlaxoSmithKline
  • Boehringer Ingelheim
  • Bristol-Myers Squibb
  • Novartis
  • Celgene
  • Amgen
  • Pfizer
  • Merck

第 15 章 DataM

简介目录
Product Code: DMPH2179

Market Overview

Ovarian Cancer Market was valued at US$ YY million in 2021 and is estimated to reach US$ YY million by 2029, growing at a CAGR of 16% during the forecast period (2022-2029).

Ovarian cancer is the deadly gynecological cancer and is the seventh most common cancer in women globally. Most women with ovarian cancer are diagnosed at the advanced stage, which is most challenging to treat. Chemotherapy and Surgery are usually used in the treatment of ovarian cancer.

Market Dynamics

The major driving forces are rising ovarian cancer incidence, a growing number of clinical trials for innovations, increasing health expenditure, the use of combination therapies to treat ovarian cancer, and an increasing geriatric population.

The increasing burden of ovarian cancer and the growing female geriatric population drive global market growth.

The growing prevalence and female geriatric population are fueling the global market growth. For instance, according to the World Cancer Research Fund International, ovarian cancer is the 8th most commonly occurring cancer in women and the 18th most common cancer overall. As per the NIH, there were more than 313,000 new cases of ovarian cancer in 2020, and a total of 207,252 new deaths from ovarian cancer were reported globally; ovarian carcinoma is the most common type of ovarian cancer, comprising over 90% of all ovarian cancer cases. Furthermore, according to the NIH, the risk of ovarian cancer increases in females with age; therefore, the growing female geriatric population drives the global market growth. For instance, 727 million persons aged 65 years or over in 2020. Since women live longer than men, they comprise the majority of older persons, especially at advanced ages.

The costly cancer treatment is restraining the global Ovarian Cancer growth.

However, the high cost of cancer treatment, lack of accurate diagnosis of ovarian cancer, and lack of awareness in emerging and low-income economies are expected to restrain the market. For patients without health insurance, the cost ranges from $20,000 to $200,000 or more for treatment with surgery and chemotherapy for advanced cancer.

Global Ovarian Cancer Market-Industry analysis.

The global ovarian cancer report will provide an in-depth analysis of the market based on various industry factors such as porter`s five forces, innovations, new product launches, pricing, pipeline analysis Etc.

Segment Analysis

The imaging test market is expected to have a greater grasp of the Ovarian Cancer market during the forecast period (2022-2029)

Epithelial ovarian cancer dominated the global market in 2021. It is expected to show a similar trend throughout the forecast period (2022-2029), as epithelial cancer is the most common type of ovarian cancer. A large number of clinical research is ongoing. For instance, according to Cancer Research UK, about 90 out of 100 tumors of the ovary (90%) are epithelial, and according to the ClinicalTrails.Gov, over 200 interventional studies are active for epithelial ovarian cancer examples of a few are a phase III Randomized Study Evaluating Hyperthermic Intra-Peritoneal Chemotherapy (HIPEC) for treatment of relapse ovarian cancer, a phase II pharmacological study with Wee-1 inhibitor MK-1775 combined with carboplatin in patients with p53 mutated epithelial ovarian cancer and early relapse (< 3 months) or progression during standard first-line treatment, a GINECO phase II trial for the assessment of safety and the efficacy of the Bevacizumab, Olaparib and Durvalumab (MEDI 4736) combination in patients with advanced epithelial ovarian cancer in relapse, a phase 3, single-arm study of Mirvetuximab Soravtansine in platinum-resistant, advanced high-grade epithelial ovarian, primary peritoneal, or fallopian tube cancers with high folate receptor-alpha expression and many more.

Geographical Analysis

The Asia Pacific is expected to command dominating the global ovarian cancer market.

The Asia Pacific is predicted to command the global ovarian cancer market since the Asia Pacific has the highest prevalence of ovarian cancer and the largest portion of the global population. For instance, according to the statistics from the WHO, in 2020, Eastern Asia had 71 353 new cases and 45 690 deaths due to ovarian cancer, South-Eastern Asia had 31 169 new cases and 20 012 deaths because of ovarian cancer, South-Central Asia had 59 730 new cases and 41 407 deaths of ovarian cancer patients while Western Asia had 8 507 new cases and 5 827 deaths as a result of ovarian cancer advancement. Furthermore, the Asia Pacific has the highest populated countries in the world, India and China; for instance, in 2021, India's population was 1.412 billion, compared to China's 1.426 billion. The Asia Pacific accounts for 60% of the global population, fueling the ovarian cancer market growth in this region.

Competitive Landscape

The key players operating in the global ovarian cancer market are Roche, GlaxoSmithKline, AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Novartis, Celgene, Amgen, Pfizer, and Merck. The key players are adopting various strategies such as product launches, mergers & acquisitions, partnerships, and collaborations, contributing to the growth of the ovarian cancer market globally. For instance, on 16 August 2022, GSK acquired Affinivax, Inc. Also, on December 22, 2021, Novartis acquired Gyroscope Therapeutics.

AstraZeneca plc

Overview:

AstraZeneca plc is a leading pharmaceutical and biotechnology company dealing with oncology, cardiovascular, gastrointestinal, infection, neuroscience, respiratory, and inflammation. AstraZeneca plc was founded in 1999 and is headquartered in Cambridge, UK.

Product Portfolio:

The product portfolio of AstraZeneca plc for ovarian cancer has LYNPARZA.

The global ovarian cancer report would provide access to approximately 40+ market data tables, 45+ figures, and in the range of 200 (approximate) pages.

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Market Definition and Overview

3. Executive Summary

4. Market Dynamics

  • 4.1. Market Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. The Increasing Burden of Ovarian Cancer
      • 4.1.1.2. Rising Female Geriatric Population
    • 4.1.2. Restraints
      • 4.1.2.1. High Cost
      • 4.1.2.2. Lack of Treatment Options
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's Five Forces Analysis
  • 5.2. Supply Chain Analysis
  • 5.3. Regulatory Analysis

6. COVID-19 Analysis

  • 6.1. Analysis of Covid-19 on the Market
    • 6.1.1. Before COVID-19 Market Scenario
    • 6.1.2. Present COVID-19 Market Scenario
    • 6.1.3. After COVID-19 or Future Scenario
  • 6.2. Pricing Dynamics Amid Covid-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During Pandemic
  • 6.5. Manufacturer's Strategic Initiatives
  • 6.6. Conclusion

7. By Type

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type Segment
    • 7.1.2. Market Attractiveness Index, By Type Segment
  • 7.2. Epithelial Ovarian Cancer
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis, US$ Million, 2021-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 7.3. Germ Cell Ovarian Cancer
  • 7.4. Stromal Cell Ovarian Cancer
  • 7.5. Small Cell Ovarian Cancer

8. By Treatment Type

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Type Segment
    • 8.1.2. Market Attractiveness Index, By Treatment Type Segment
  • 8.2. Targeted Therapy
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis, US$ Million, 2021-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 8.3. Surgery
  • 8.4. Chemotherapy
  • 8.5. Immunotherapy
  • 8.6. Others

9. By Diagnosis Type

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Diagnosis Type Segment
    • 9.1.2. Market Attractiveness Index, By Diagnosis Type Segment
  • 9.2. Blood Tests
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis, US$ Million, 2021-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 9.3. Imaging Tests
  • 9.4. Laparoscopy
  • 9.5. Colonoscopy
  • 9.6. Others

10. By Drug class

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Class Segment
    • 10.1.2. Market Attractiveness Index, By Drug Class Segment
  • 10.2. PARP Inhibitors
    • 10.2.1. Introduction
    • 10.2.2. Market Size Analysis, US$ Million, 2021-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 10.3. Angiogenesis Inhibitors
  • 10.4. PD-L1 Inhibitors

11. By End User

  • 11.1. Introduction
    • 11.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User Segment
    • 11.1.2. Market Attractiveness Index, By End User Segment
  • 11.2. Hospitals And Clinics
    • 11.2.1. Introduction
    • 11.2.2. Market Size Analysis, US$ Million, 2021-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 11.3. Diagnostic Centers
  • 11.4. Cancer Research Centers
  • 11.5. Other

12. By Region

  • 12.1. Introduction
    • 12.1.1. Market Size Analysis, US$ Million, 2021-2029 and Y-o-Y Growth Analysis (%), 2021-2029, By Region
    • 12.1.2. Market Attractiveness Index, By Region
  • 12.2. North America
    • 12.2.1. Introduction
    • 12.2.2. Key Region-Specific Dynamics
    • 12.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
    • 12.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Type
    • 12.2.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Diagnosis Type
    • 12.2.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Class
    • 12.2.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
    • 12.2.8. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 12.2.8.1. The U.S.
      • 12.2.8.2. Canada
      • 12.2.8.3. Mexico
  • 12.3. Europe
    • 12.3.1. Introduction
    • 12.3.2. Key Region-Specific Dynamics
    • 12.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
    • 12.3.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Type
    • 12.3.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Diagnosis Type
    • 12.3.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Class
    • 12.3.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
    • 12.3.8. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 12.3.8.1. Germany
      • 12.3.8.2. The U.K.
      • 12.3.8.3. France
      • 12.3.8.4. Italy
      • 12.3.8.5. Spain
      • 12.3.8.6. Rest of Europe
  • 12.4. South America
    • 12.4.1. Introduction
    • 12.4.2. Key Region-Specific Dynamics
    • 12.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
    • 12.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Type
    • 12.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Diagnosis Type
    • 12.4.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Class
    • 12.4.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
    • 12.4.8. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 12.4.8.1. Brazil
      • 12.4.8.2. Argentina
      • 12.4.8.3. Rest of South America
  • 12.5. Asia Pacific
    • 12.5.1. Introduction
    • 12.5.2. Key Region-Specific Dynamics
    • 12.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
    • 12.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Type
    • 12.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Diagnosis Type
    • 12.5.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Class
    • 12.5.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
    • 12.5.8. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 12.5.8.1. China
      • 12.5.8.2. India
      • 12.5.8.3. Japan
      • 12.5.8.4. Australia
      • 12.5.8.5. Rest of Asia Pacific
  • 12.6. Middle East and Africa
    • 12.6.1. Introduction
    • 12.6.2. Key Region-Specific Dynamics
    • 12.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
    • 12.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Type
    • 12.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Diagnosis Type
    • 12.6.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Class
    • 12.6.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User

13. Competitive Landscape

  • 13.1. Key Developments and Strategies
  • 13.2. Company Share Analysis
  • 13.3. Product Benchmarking

14. Company Profiles

  • 14.1. AstraZeneca
    • 14.1.1. Company Overview
    • 14.1.2. Product Portfolio and Description
    • 14.1.3. Key Highlights
    • 14.1.4. Financial Overview
  • 14.2. Roche
  • 14.3. GlaxoSmithKline
  • 14.4. Boehringer Ingelheim
  • 14.5. Bristol-Myers Squibb
  • 14.6. Novartis
  • 14.7. Celgene
  • 14.8. Amgen
  • 14.9. Pfizer
  • 14.10. Merck

LIST NOT EXHAUSTIVE

15. DataM

  • 15.1. Appendix
  • 15.2. About Us and Services
  • 15.3. Contact Us